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Abstract
Background:  Recent studies suggest that hypercholesterolemia, an established risk factor for
atherosclerosis, is also a risk factor for Alzheimer's disease. The myeloid scavenger receptor CD36 binds
oxidized lipoproteins that accumulate with hypercholesterolemia and mediates their clearance from the
circulation and peripheral tissues. Recently, we demonstrated that CD36 also binds fibrillar β-amyloid and
initiates a signaling cascade that regulates microglial recruitment and activation. As increased lipoprotein
oxidation and accumulation of lipid peroxidation products have been reported in Alzheimer's disease, we
investigated whether β-amyloid altered oxidized lipoprotein clearance via CD36.
Methods: The availability of mice genetically deficient in class A (SRAI & II) and class B (CD36) scavenger
receptors has facilitated studies to discriminate their individual actions. Using primary microglia and
macrophages, we assessed the impact of Aβ on: (a) cholesterol ester accumulation by GC-MS and neutral
lipid staining, (b) binding, uptake and degradation of 125I-labeled oxidized lipoproteins via CD36, SR-A and
CD36/SR-A-independent pathways, (c) expression of SR-A and CD36. In addition, using mice with
targeted deletions in essential kinases in the CD36-signaling cascade, we investigated whether Aβ-CD36
signaling altered metabolism of oxidized lipoproteins.
Results: In primary microglia and macrophages, Aβ inhibited binding, uptake and degradation of oxidized
low density lipoprotein (oxLDL) in a dose-dependent manner. While untreated cells accumulated
abundant cholesterol ester in the presence of oxLDL, cells treated with Aβ were devoid of cholesterol
ester. Pretreatment of cells with Aβ did not affect subsequent degradation of oxidized lipoproteins,
indicating that lysosomal accumulation of Aβ did not disrupt this degradation pathway. Using mice with
targeted deletions of the scavenger receptors, we demonstrated that Aβ inhibited oxidized lipoprotein
binding and its subsequent degradation via CD36, but not SRA, and this was independent of Aβ-CD36-
signaling. Furthermore, Aβ treatment decreased CD36, but not SRA, mRNA and protein, thereby reducing
cell surface expression of this oxLDL receptor.
Conclusions: Together, these data demonstrate that in the presence of β-amyloid, CD36-mediated
clearance of oxidized lipoproteins is abrogated, which would promote the extracellular accumulation of
these pro-inflammatory lipids and perpetuate lipid peroxidation.
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Background
Hypercholesterolemia is an established risk factor for
atherosclerosis and a number of recent epidemiological
studies have suggested a link between increased circulat-
ing cholesterol levels and Alzheimer's disease (AD) [1].
Lipoproteins in the serum and the central nervous system
(CNS) mediate cholesterol homeostasis through the
delivery and removal of cellular cholesterol. With hyperc-
holesterolemia, these phospholipid and cholesterol rich-
particles accumulate abnormally outside the arterial
lumen, where they are susceptible to oxidization [2].
Lipoprotein-derived oxidation products (hydroperoxides,
lysophosphatidylcholine, oxysterols and aldehydes) initi-
ate the inflammatory response that drives atherosclerotic
plaque formation in the artery wall, and these lipid perox-
idation products, including malondialdehyde and 4-
hydroxynonal (HNE), have also been detected in AD-
affected brains [3,4]. AD patients have been reported to
have cholesterol profiles known to be pro-atherosclerotic,
including increased total serum and low-density lipopro-
tein (LDL) cholesterol, and increased susceptibility to
lipoprotein oxidation [5-9]. Antibodies raised against oxi-
dized LDL (oxLDL) demonstrate reactivity to amyloid
plaques and surrounding tissue, indicating that lipid per-
oxidation epitopes present in oxLDL accumulate in the
brains of AD patients [3]. Recently, oxidized cholesterol
metabolites identified in both atherosclerotic and senile
plaques have been found to accelerate β-amyloid fibril
formation [10]. Together, these findings suggest that, as in
atherosclerosis, the accumulation of lipoprotein oxida-
tion products in Alzheimer's disease may contribute to
chronic inflammation.
Phagocyte expressed pattern recognition receptors (PRR)
are the first line of defense of the innate immune system
against foreign or modified proteins and lipids. Scavenger
receptors are pattern recognition receptors that bind and
internalize a wide range of ligands, including certain poly-
anions, modified forms of LDL, advanced glycation end-
products and apoptotic cells [11]. These receptors are
expressed by macrophages and microglia, and are the pri-
mary clearance pathway for pro-inflammatory oxidized
lipoproteins [12]. In addition to binding oxLDL, several
members of the scavenger receptor A (SRA) and B (CD36,
SR-B1) class recognize fibrillar β-amyloid (Aβ), which
accumulates in the brain and cerebral blood vessels in AD,
as well as in coronary atherosclerotic plaques [13-15].
While studies in Sra null mice have failed to show a role
for this receptor in the pathogenesis of AD [16], it has
recently been demonstrated in our lab, and others, that Aβ
activates an inflammatory signaling cascade via CD36 that
regulates microglial activation and recruitment in the
brain [17-19]. In AD patients, increased CD36 expression
was detected in the frontal cortex which correlated with
the presence of amyloid plaques and oxidative markers,
suggesting that upregulation of this scavenger receptor
pathway may also promote inflammation in vivo [20].
Similar to its role in peripheral macrophages, CD36 on
microglia is believed to scavenge modified proteins and
oxidized phospholipids. We hypothesized that a simulta-
neous increase in lipoprotein oxidation and accumula-
tion of Aβ in the brain and blood vessels in AD might
compromise the ability of this scavenger receptor to effec-
tively clear these modified host ligands.
Aβ has previously been shown to reduce uptake of LDL
modified by acetylation, in microglia and SRA- or SR-B1-
transfected cells [21]. We have shown that CD36 binds
acetylated LDL with very low affinity, indicating that these
studies primarily addressed the impact of Aβ on Class A
scavenger receptor activity [12]. Unlike SR-A, which binds
the modified apolipoprotein B component of acetylated
LDL, CD36 recognizes oxidized phospholipids within the
oxidized lipoprotein particle [22]. CNS lipoproteins iso-
lated from cerebrospinal fluid, astrocytes or microglia,
contain similar amounts of phospholipid, cholesterol,
and cholesteryl ester content as their serum counterparts,
and a pro-oxidative environment in Alzheimer's disease is
believed to accelerate the formation of lipid peroxides in
these particles [23]. In this study, we assessed the impact
of Aβ on the binding and degradation of oxLDL via CD36,
SR-A and CD36/SR-A-independent pathways. The availa-
bility of mice genetically deficient in Sra and Cd36 has
facilitated studies to discriminate the actions of these indi-
vidual scavenger receptors. We show that Aβ dose-
dependently inhibits oxLDL binding, lysosomal degrada-
tion and cholesterol ester accumulation in macrophages
and microglia. This inhibitory effect was mediated specif-
ically via CD36 and could be reversed by removal of extra-
cellular Aβ, indicating that the lysosomal degradation
pathway was not directly impaired. Furthermore, activa-
tion of CD36-signaling by Aβ did not mediate this inhib-
itory effect, as targeted inactivation of essential
downstream kinases did not restore oxLDL degradation.
Together, these data demonstrate that Aβ impairs the abil-
ity of CD36 to scavenge oxidized lipids by competing for
receptor binding. This suggests that accumulation of Aβ in
the brain and vessel wall in AD would inhibit the clear-
ance of pro-inflammatory oxidized phospholipids and
oxidized-phospholipid-containing particles such as lipo-
proteins, thereby promoting lipid peroxidation.
Methods
β-Amyloid
Aβ1-42 and reverse Aβ42-1 (revAβ) peptides were obtained
from Biosource International (Camarillo, California). To
induce fibril formation, Aβ1-42 was resuspended in H2O at
1 mg/ml and incubated for 1 week (37°C) and fibril for-
mation was confirmed by thioflavine S (Sigma-AldrichJournal of Neuroinflammation 2004, 1:23 http://www.jneuroinflammation.com/content/1/1/23
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Co., St. Louis, Missouri) fluorescent staining as we previ-
ously described [17,18].
Mice
The Cd36-/- mice were generated in our laboratory as pre-
viously described [17] and SraI/II null (Sra-/-) mice were
generously provided from Dr. T. Kodama (University of
Tokyo, Japan) [24]. Both mouse lines were backcrossed to
C57BL/6 mice for 7 generations (98.6% C57BL/6) prior
to intercrossing to generate mice lacking both Sra and
Cd36. Double knockout mice (Sra-/-/Cd36-/-) were gener-
ated from heterozygote intercrosses at the expected ration
of 1:16. Wild type age-matched C57BL/6 mice (The Jack-
son Laboratory, Bar Harbor, Maine) were used as controls
for these three lines. Lyn-/- and Fyn-/- mice were obtained
from The Jackson Laboratory and Lyn-/-, Fyn-/- and wild
type littermate control mice were generated from hetero-
zygote intercrosses. All mice were maintained in a patho-
gen-free facility with free access to rodent chow and water.
All experimental procedures were carried out in accord-
ance with Massachusetts General Hospital's institutional
guidelines for use of laboratory animals.
Primary macrophage and microglial culture
Macrophages were collected from 6–8 week old mice by
peritoneal lavage 4 days after i.p. injection with 3% thi-
oglycollate as we previously described [17,25]. Cells were
washed in PBS, cultured for 2 h in DMEM with 5% FCS,
and washed again to remove non-adherent cells. Adherent
cells were incubated in DMEM with 1% FCS overnight
prior to use and were routinely >95% CD11b+ and F4/80+
as determined by flow cytometric analysis. Primary micro-
glia were prepared from mixed brain cultures of neonatal
mice as we previously described [17]. Briefly, whole
brains were incubated in 0.25% trypsin and 1 mM EDTA
(10 min, 25°C) and dissociated to obtain a single cell-sus-
pension. Cells were washed in HBSS (4x, 10 min) and cul-
tured in DMEM containing 10% FCS, 1% Fungizone for
10–12 days. Microglia accumulating above astrocyte
monolayers were collected after gentle agitation, washed
and incubated in DMEM with 1% FCS overnight prior to
use. Microglia prepared in this manner were routinely
>95% CR3+ and express SR-A and CD36 [14,17,18].
Lipoproteins
Human 125I-LDL and LDL (d = 1.019 - 1.063) were pur-
chased from Biomedical Technologies (Stoughton, Massa-
chusetts) and oxidized as we previously described [12,26].
LDL was diluted to 250 µg/ml, dialyzed against PBS at
4°C to remove EDTA, and then dialyzed against 5 µM
CuSO4 in PBS at 37°C for 6 or 10 h. Oxidation was termi-
nated by the addition of 50 µM butylated hydroxytoluene
and 200 µM EDTA and oxLDL was used within 2 days of
preparation. Moderately oxidized LDL (6 h oxidation)
had a relative electrophoretic mobility of approximately
2.5–3 times that of native, unmodified LDL, whereas
extensively oxidized LDL (10 h oxidation) had a relative
mobility four times that of native LDL.
125I-OxLDL degradation, binding and uptake assays
Measurement of 125I-oxLDL binding, degradation and
uptake was performed on confluent monolayers of perito-
neal macrophages (7 × 105) and microglia (5 × 105) in 24
well plates as we previously described [12,26]. Briefly, 10
µg/ml of 125I-oxLDL was added to cells in the presence or
absence of 30-fold excess unlabeled oxLDL, native LDL,
Aβ1-42, or revAβ peptide for 5 h at 37°C. To measure 125I-
oxLDL degradation, media were removed and assayed for
TCA-soluble non-iodide degradation products. To meas-
ure  125I-oxLDL binding in the presence Aβ1-42 or revAβ,
cells were washed 3x with 50 mM Tris pH 7.4, 0.15 N
NaCl and 2 mg/ml BSA, 1x with 50 mM Tris pH 7.4 and
0.15 N NaCl and treated with 0.4% dextran sulfate to
release surface bound 125I-oxLDL [27]. To measure 125I-
oxLDL uptake, cells were washed 3x in 50 mM Tris pH 7.4
and 0.15 N NaCl, lysed in 0.1 N NaOH and assayed for
125I and cellular protein content. In some experiments,
cell-association of oxLDL (cell-surface bound and endocy-
tosed oxLDL) was measured by omitting the dextran sul-
fate treatment. Cellular protein content was measured by
BCA assay (Pierce, Rockford, IL) and degradation, binding
and uptake activity are expressed as ng 125I-oxLDL/mg
protein. Specific degradation was calculated as the differ-
ence of total cellular degradation of 125I-oxLDL in the
presence and absence of 30-fold excess unlabelled oxLDL
competitor. All measurements were performed in tripli-
cate and are representative of at least 3 experiments.
Analysis of cellular cholesterol content
Macrophages and microglia were cultured with 40 µg/ml
of oxLDL for 48 h in the presence or absence of Aβ1-42 or
revAβ. Cholesterol ester accumulation was assessed by gas
chromatography-mass spectrometry (GC-MS) and oil red
O staining as we previously described [12,26]. For GC-MS
analysis, lipids were extracted with hexane:isopropanol
(3:2) and stigmasterol (Sigma, St. Louis, Missouri) was
added as an internal standard. Lipid extracts were washed
once with water and divided equally. One lipid aliquot
was saponified for determination of total cholesterol and
the second aliquot analyzed for free cholesterol using gas
chromatography-mass spectrometry. The samples were
injected (splitless) into an Agilent 6890 GC-MS-(G2613A
system, Agilent Technologies, Palo Alto, CA) equipped
with a J&W DB17 fused silica capillary column (15 m ×
0.25 mm inner diameter × 0.5 µm; J&W Scientific, Fol-
som, CA). The GC temperature program was as follows:
the initial temperature was 260°C for 5 min, then
increased to 280°C (5°C/min) and held 280°C for 11
min. A model 5973N mass-selective detector (Agilent
Technologies) was used in scan modes to identify theJournal of Neuroinflammation 2004, 1:23 http://www.jneuroinflammation.com/content/1/1/23
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samples. Cholesterol measurements were made in tripli-
cate and normalized to cellular protein content. Choles-
terol ester content was calculated by subtracting free
cholesterol from total cholesterol measured after saponi-
fication. To assess neutral lipid accumulation, cells were
fixed in 4% paraformaldehyde and stained with oil red O
for 30 min. Staining was recorded on an Olympus X10
microscope equipped with a digital camera.
Real time RT-PCR analysis
Total RNA was extracted using Trizol B reagent and real-
time quantitative RT-PCR (QRT-PCR) was performed
using the QuantiTect SYBR Green PCR kit (Qiagen Inc,
Valencia, CA) as we previously described [17,18]. Each
reaction contained 0.3 µM of CD36, SRA or GAPDH prim-
ers, 3 µl of cDNA, SYBR Green, and HotStarTaq polymer-
ase. PCR was performed using a BioRad iCycler under the
following conditions: 15 min at 95°C, followed by 30
cycles of 30 sec at 95°C, 30 sec at 55°C and 30 sec at
72°C. Each sample was analyzed in triplicate and the
amount of CD36, SRA and GAPDH mRNA in each sample
was calculated from a standard curve of known template.
Data are expressed as the mean number of CD36 and SRA
molecules normalized to GAPDH.
Western analysis
Cells were washed in ice-cold PBS and lysed in radioim-
mune precipitation buffer containing protease and phos-
phatase inhibitors. For detection of CD36, 30 µg of
protein was run on an 8% denaturing SDS-polyacryla-
mide gel, transferred to nitrocellulose and blocked over-
night in 5% nonfat dry milk and 3% BSA in Tris-buffered
saline containing 0.1% Tween 20 (TBS-T) as we previously
described [17,26]. Membranes were incubated with a rab-
bit anti-CD36 antiserum (1:500 dilution) generated in
our laboratory [17] for 2 hours, washed three times in
TBS-T, and incubated with horseradish peroxidase-conju-
gated anti-rabbit IgG (1:10,000 dilution) for 1 hour. Blots
were washed 3x in TBS-T, exposed to ECL reagent (Amer-
sham Biosciences, Piscataway, NJ), and signal was
recorded and quantified using an Alpha Innotech
Fluorchem 8800 image analysis system. Blots were
stripped and probed with an anti-actin rabbit polyclonal
antibody (Santa Cruz Biotechnology) as described above
as an internal standard for equivalent loading.
Results
β-Amyloid blocks oxidized LDL metabolism and cellular 
cholesterol accumulation in macrophages and microglia
Treatment of peritoneal macrophages with Aβ1-42, but not
revAβ, dose-dependently inhibited lysosomal degradation
of 125I-oxLDL (Fig. 1a). Half-maximal inhibition of mac-
rophage 125I-oxLDL degradation was achieved with 10 µM
Aβ1-42. This was equivalent to the inhibitory effect of 15-
fold excess of unlabelled oxLDL competitor (Fig. 1b). At
20 µM, Aβ1-42 reduced macrophage degradation of 125I-
oxLDL by up to 90%, while treatment with the same con-
centration of non-fibrillar revAβ peptide reduced degrada-
tion by only 10%, and this concentration was selected for
all further experiments. Because engulfment of Aβ1-42 has
previously been reported to disrupt endosomal/lysosomal
integrity in a neuronal cell line [28], we investigated
whether the observed reduction in oxLDL degradation
could be attributed to lysosomal accumulation of Aβ1-42
which occurs within 1 h of treatment. After exposure to
Aβ1-42 for 3 hours, macrophages were washed extensively
to remove extracellular Aβ1-42 and exposed to 125I-oxLDL
or 125I-oxLDL + Aβ1-42 for 5 h. While cells continuously
exposed to Aβ1-42  showed a profound impairment of
oxLDL degradation, cells pre-treated with Aβ1-42 were sim-
ilar to untreated and revAβ-treated cells, indicating that
intracellular accumulation of Aβ1-42 does not block subse-
quent lysosomal degradation of oxLDL (Fig. 1c).
The inhibition of 125I-oxLDL degradation by Aβ1-42 would
be predicted to reduce cellular cholesterol ester accumula-
tion. Excess unesterified "free" cholesterol is cytotoxic and
is thus rapidly converted by the microsomal enzyme acyl-
coenzyme A:cholesterol acyltransferase (ACAT) to choles-
terol ester for storage. This neutral lipid is retained in cyto-
plasmic lipid droplets for storage and/or efflux from the
cell. Using gas chromatograpy-mass spectrometry, we
quantified the cholesterol ester content of macrophages
treated with oxLDL in the presence and absence of Aβ1-42.
As expected, untreated cells did not contain measurable
cholesterol ester, while macrophages treated with 40 µg/
ml oxLDL for 48 h accumulated approximately 80 µg cho-
lesterol ester/mg cellular protein (Fig. 1d). By contrast,
macrophages treated with both oxLDL and Aβ1-42 showed
no measurable cholesterol ester accumulation after 48 h,
similar to untreated cells.
As seen in peripheral macrophages, Aβ1-42 substantially
inhibited 125I-oxLDL binding, uptake, and degradation by
primary microglia indicating that it has a similar effect on
lipoprotein metabolism in these two myeloid cell types
(Fig. 2a,2b,2c). In the presence of 20 µM Aβ1-42, microglia
demonstrated a 55% reduction in 125I-oxLDL binding, an
80% reduction in 125I-oxLDL uptake and a 95% reduction
of  125I-oxLDL degradation. The absence of cholesterol
ester in oxLDL treated microglia exposed to Aβ1-42 was
confirmed by staining cells with the neutral lipid stain oil
red O. Microglia treated with oxLDL alone demonstrate
oil red O positive lipid droplets in their cytoplasm charac-
teristic of cholesterol ester storage (Fig. 2d). However, in
the presence of Aβ1-42, oxLDL treated microglia show a
dramatic reduction in lipid droplets that is not seen with
treatment with the same concentration of revAβ. As
expected, cells treated with Aβ1-42 or revAβ alone do not
accumulate cholesterol ester in the absence ofJournal of Neuroinflammation 2004, 1:23 http://www.jneuroinflammation.com/content/1/1/23
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Aβ inhibits lysosomal degradation of oxidized LDL and cholesterol ester accumulation in macrophages Figure 1
Aβ inhibits lysosomal degradation of oxidized LDL and cholesterol ester accumulation in macrophages. A. Fibrillar Aβ, but not 
revAβ, dose-dependently inhibits lysosomal degradation of 125I-oxLDL by macrophages, similar to unlabeled oxLDL competitor 
(B). C. Intracellular accumulation of Aβ does not block lysosomal degradation of 125I-oxLDL. Macrophages were pretreated 
with 20 µM Aβ or revAβ for 3 hours to allow intracellular accumulation, washed extensively to remove extracellular peptide 
and degradation of 125I-oxLDL over 5 h was measured in the absence (PT) or presence of additional peptide. D. Aβ blocks cho-
lesterol ester accumulation in oxLDL treated macrophages. Cellular lipids were extracted from macrophages treated with 
oxLDL (40 µg/ml) for 48 h in the presence or absence of 20 µM Aβ and analyzed by gas-chromatography mass-spectrometry. 
Cholesterol ester content was normalized to cellular protein. (A-D) Data are the mean of triplicate samples ± standard devia-
tion, *p ≤ 0.005.
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exogenously added oxLDL (Fig. 2d). Similar results were
observed in macrophages (data not shown). Together,
these data demonstrate that Aβ blocks cholesterol ester
accumulation in macrophages and microglia by inhibit-
ing oxLDL clearance.
fAβ downregulates expression of the OxLDL receptor 
CD36
To address the mechanism by which Aβ1-42 inhibits oxLDL
metabolism, we first evaluated cellular expression of the
scavenger receptors SRA and CD36. Fibrillar Aβ1-42
reduced expression of CD36 mRNA by 40 and 60% after
6 and 24 h, respectively (Fig. 3a), but showed no effect on
macrophage expression of SRA. Western blotting con-
firmed a 40% decrease in CD36 protein in Aβ1-42 treated
macrophages (Figure 3b), which would be expected to
reduce the ability of these cells to bind oxLDL.
Aβ inhibits oxLDL binding, uptake and degradation in microglia Figure 2
Aβ inhibits oxLDL binding, uptake and degradation in microglia. Treatment of primary microglia with 20 µM fibrillar Aβ, but 
not revAβ, inhibits 125I-oxLDL binding (A), cellular uptake (B) and degradation (C). Data are the mean of triplicate samples ± 
standard deviation, *p ≤ 0.005. (D) Microglia treated with 20 µM fibrillar Aβ fail to accumulate cholesterol ester in the pres-
ence of oxLDL. Microglia were incubated with 40 µg/ml oxLDL for 48 h in the presence and absence of 20 µM Aβ or revAβ 
peptide and stained with oil red O to visualize neutral lipid. Cells treated with oxLDL alone or in the presence of revAβ dem-
onstrate the accumulation of red-stained lipid droplets in the cytoplasm. By contrast, oil red O staining is greatly reduced in 
oxLDL and Aβ co-treated microglia. Mag. 200X.
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Aβ downregulates expression of the oxLDL receptor CD36 Figure 3
Aβ downregulates expression of the oxLDL receptor CD36. A. Analysis of CD36 and SRA mRNA in peritoneal macrophages 
treated with Aβ (20 µM) by quantitative RT-PCR. Data represent the mean of triplicate samples ± standard deviation, *p ≤ 
0.005. B. Western blot analysis confirming CD36 protein downregulation by Aβ. The signal was recorded and the integrated 
density value quantified using an Alpha Innotech FluorChem Imager and normalized to actin protein. Data are representative of 
2 experiments.
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fAβ competes for oxLDL binding to CD36, but not SRA
β-Amyloid has previously been reported to bind to the
class A scavenger receptors SRA I & II and to block uptake
of LDL modified by acetylation [14,21]. We employed Sra
and Cd36 single null mice to investigate the role of these
receptors in the inhibition of oxLDL clearance by Aβ1-42.
In addition, we used Sra/Cd36 double null mice to evalu-
ate the role of SRA/CD36-independent mechanisms,
including those of additional scavenger receptor family
members. Because of the difficulty of culturing sufficient
numbers of primary microglia for binding and degrada-
tion experiments, studies involving knock-out mice were
performed with peritoneal macrophages. In Sra-/- and wild
type macrophages Aβ1-42 blocked cell association (binding
and uptake) of 125I-oxLDL by greater than 50%, indicating
that this scavenger receptor is not essential for the inhibi-
tory action of Aβ (Fig. 4a). By contrast, in the absence of
Cd36, impairment of 125I-oxLDL cell association by Aβ1-42
was reduced to 8%, indicating that this receptor was the
primary target of Aβ1-42 inhibition (Fig. 4a).
The finding that CD36 is required for Aβ1-42 inhibition of
oxLDL suggests two possible mechanisms of action: (1)
direct competition for CD36 binding, or (2) inhibition of
oxLDL metabolism as a result of Aβ/CD36 signal trans-
duction. To address whether CD36 signaling inhibits cel-
lular oxLDL degradation, we used macrophages with
targeted deletions in two kinases in this pathway, Lyn and
Fyn, which have previously been shown to be required for
CD36-mediated p44/42 activation, MCP-1 secretion and
ROS production [17]. However, as in wild type macro-
phages, Aβ1-42 effectively inhibited 125I-oxLDL degrada-
tion in Lyn-/- and Fyn-/- macrophages, suggesting that this
signaling pathway does not inhibit oxLDL metabolism
(Fig. 4b). Furthermore, treatment of macrophages with
the general phosphotyrosine kinase inhibitor genistein
did not reverse Aβ1-42 inhibition of 125I-oxLDL degrada-
tion, confirming that phosphotyrosine kinase signaling
does not mediate this effect of Aβ1-42 (data not shown).
Interestingly, in untreated Fyn-/- macrophages 125I-oxLDL
degradation was increased 2-fold (Fig. 4b) indicating that
this kinase may play a role in regulating oxLDL uptake.
However, despite a doubling of oxLDL degradation in Fyn-
/- macrophages, this process was still inhibited by Aβ1-42 by
up to 90%. Together, these experiments suggest that Aβ1-
42 inhibition of oxLDL metabolism is not the result of
CD36-Lyn/Fyn signal transduction and support the
hypothesis that Aβ1-42 competes for oxLDL binding to
Inhibition of oxLDL cell-association by Aβ requires CD36, but not CD36-associated signal transduction Figure 4
Inhibition of oxLDL cell-association by Aβ requires CD36, but not CD36-associated signal transduction. A. To determine 
whether SRA or CD36 was essential for Aβ-inhibition of oxLDL metabolism, cell-association of 125I-oxLDL was measured in 
wild type, Sra-/- and Cd36-/- macrophages in the presence or absence of 20 µM Aβ. While Aβ blocked oxLDL association by 
approximately 50% in wild type and Sra-/- macrophages, this effect was lost in Cd36-/- macrophages indicating that CD36 is 
required for this inhibition. B. Inhibition of 125I-oxLDL degradation by Aβ does not utilize the Aβ-CD36 signaling pathway 
involving Lyn and Fyn kinases. Aβ impaired oxLDL degradation to a similar extent in wild type, and Lyn-/- or Fyn-/- macrophages 
in which CD36-signaling is impaired, indicating that this signal transduction pathway is not required, Data are the mean of trip-
licate samples ± standard deviation, *p ≤ 0.005.
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CD36. Analysis of 125I-oxLDL cell-surface binding showed
that Aβ inhibited 125I-oxLDL binding by approximately
60% in wild type macrophages (Fig. 5). This inhibitory
effect was lost in Cd36-/- macrophages, confirming that Aβ
inhibited oxLDL binding to this receptor. Of note, wild
type macrophages bound 60% more oxLDL than
macrophages lacking Cd36  as has previously been
reported, and this correlated with the percentage reduc-
tion of oxLDL binding by Aβ in wild type macrophages
(57%), suggesting that the CD36-dependent contribution
to oxLDL binding was totally inhibited. To confirm that
other myeloid scavenger receptors were not inhibited by
Aβ, assesed 125I-oxLDL binding in Sra-/-Cd36-/-  macro-
phages. No effect of Aβ was observed in these cells, dem-
onstrating the specificity of Aβ inhibition of oxLDL
binding to CD36.
Discussion
Numerous studies have demonstrated elevated markers of
lipid peroxidation in the brains, CSF and plasma of Alzhe-
imer's disease patients, including thiobarbituric acid-reac-
tive substances, 4-hydroxy-2-nonenal (HNE), acrolein
and F2-isoprostanes, which are suggestive of a persistent
pro-oxidant environment [3,4,9,29,30]. Lipoprotein par-
ticles are especially vulnerable to free-radical mediated
lipid peroxidation and the resulting peroxy fatty acids are
highly unstable, readily decomposing to form peroxy and
alkoxy radicals that further promote oxidation. This self-
propagating cycle of lipid peroxidation is particularly
damaging in lipid-rich tissues such as the brain, and as a
result, the innate immune system has evolved mecha-
nisms to rapidly recognize and clear oxidized lipids. The
myeloid scavenger receptors are the first lines of defense
against these non-native lipids, as well as modified host
proteins such as β-amyloid [11,31]. This dual responsibil-
ity prompted us to evaluate whether macrophages and
microglia would be compromised in their ability to
metabolize oxidized lipoproteins in the presence of Aβ.
We found that fibrillar Aβ specifically inhibited all phases
of oxLDL metabolism, including binding, uptake, degra-
dation and accumulation of cellular cholesterol ester. This
was mediated by a selective inhibition of CD36 binding
by Aβ, as well as a decrease in CD36 mRNA and protein
expression. However, inhibition of oxLDL metabolism
was independent of the recently identified Aβ-CD36-sign-
aling cascade, as targeted inactivation of essential down-
stream kinases did not restore cellular oxLDL degradation.
Together, these data demonstrate that oxidized lipopro-
tein metabolism by CD36 is profoundly impaired in the
presence Aβ, and suggest that accumulation of Aβ in the
brain and blood vessels in AD would foster the extracellu-
lar persistence of these pro-inflammatory lipids, thereby
perpetuating lipid peroxidation. Thus, Aβ binding of
CD36 in the brain would promote inflammation via two
specific mechanisms: (1) through its engagement of signal
transduction and microglial recruitment, and (2) through
its abrogation of this important clearance pathway for oxi-
dized phospholipid-containing ligands.
In addition to CD36, two other scavenger receptor family
members have been shown to be expressed in the brain
and to bind Aβ. The Class A scavenger receptors, SRA I and
II, and the class B SR-BI are expressed by neonatal micro-
glia, but unlike CD36, these receptors are not expressed by
microglia in the normal adult brain [14,15]. However,
microglial expression of SRA is increased during AD, and
this receptor can mediate both adherence to Aβ and its
phagocytosis [14,32,33]. In Sra-/- mice, there is a 60%
impairment in microglial binding of Aβ and reactive oxy-
gen production, however, AD-associated brain pathology
is not reduced [16,33]. SRA ligands, including acetylated
LDL and fucoidan, reduce Aβ uptake by microglia, how-
ever these ligands may also affect other receptors [34].
Conversely, Aβ and its soluble precursor protein, sAPPα,
inhibit macrophage and microglial uptake of acetylated
LDL [14,21,35]. While acetylated LDL is not believed to
occur physiologically, other modifications of LDL, such as
oxidation, that allow binding to SRA may also be com-
Inhibition of oxLDL binding requires CD36, but not other  scavenger receptors Figure 5
Inhibition of oxLDL binding requires CD36, but not other 
scavenger receptors. Binding of 125I-oxLDL was measured in 
wild type, Cd36-/- or Cd36/Sra-/- macrophages in the presence 
or absence of 20 µM Aβ to assess the role of CD36 and 
CD36/SRA-independent pathways. In the absence of CD36, 
oxLDL binding was not reduced by Aβ, indicating that this 
receptor is the target of Aβ inhibition. Binding of oxLDL via 
other scavenger receptors, which is measurable in Cd36/Sra-/
- macrophages, was not inhibited by Aβ. Data are representa-
tive of triplicate samples ± standard deviation, *p ≤ 0.005.
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peted by Aβ. However, in our assays Aβ inhibition of
oxLDL binding and degradation did not occur via this
pathway, similar effects were seen in wild type and Sra-/-
cells. By contrast, the effect of Aβ was abolished in the
absence of CD36, indicating that this receptor is the target
of Aβ action.
The difficulty in isolating human lipoproteins from the
CNS has limited their experimental use, however, several
groups have shown that oxidized serum lipoproteins,
including LDL, HDL and VLDL, are toxic to neurons [36-
39], and both oxLDL and oxidized CSF lipoproteins dis-
rupt neuronal microtubule organization, a pathogy char-
acteristic of the AD brain [6,38,40]. Thus, the loss of
CD36-mediated oxidized lipoprotein clearance in the
presence of Aβ1-42 would be predicted to foster inflamma-
tion and tissue injury. While we have shown that Aβ
blocks CD36 binding of oxLDL, and its subsequent degra-
dation, we would predict that similar results would be
found with oxidized lipoproteins isolated from the CNS,
astrocytes or microglia. Although serum and brain lipo-
protein particles differ in their apolipoprotein composi-
tion [23,41-44], they contain similar amounts of
cholesterol, cholesterol ester and phospholipid. CD36 has
been shown to recognize a phospholipid moiety of oxi-
dized lipoproteins, primarily oxidized phosphatidylcho-
line, which is abundant in CSF lipoproteins [22,41]. The
presence of a pro-oxidant environment in AD would be
expected to generate similar modifications of CSF lipopro-
teins and lipoproteins isolated from AD-affected individ-
uals have, in fact, been shown to be more susceptible to
oxidation [5,6]. Inhibition of the primary clearance path-
way for oxidized lipoproteins would be predicted to pro-
mote inflammation and persistence of lipid peroxidation.
Disruption of oxidized lipoprotein metabolism by Aβ
may also be relevant in the context of atherosclerosis.
Cholesterol oxidation products generated during the
inflammatory component of atherosclerosis have been
shown to accelerate β-amyloid fibril formation [10,45].
Furthermore, a recent study identified Aβ advanced
human atherosclerotic plaques [46]. Our data suggests
that the presence of Aβ in the artery wall may both prevent
macrophage oxidized LDL uptake via CD36, thereby pro-
moting β-amyloid fibril formation and activating CD36-
signaling [47]. It has recently been shown that Aβ-CD36-
signaling leads to the expression of cytokines and chem-
okines, including IL-1β, TNFα, MCP-1, MIP-1α and β and
MIP-2 [17-19]. Activation of this signaling cascade would
be predicted to promote inflammation, as well as athero-
sclerotic plaque progression. Indeed, overexpression of a
mutant human amyloid β-precursor protein in an athero-
sclerosis-susceptible mouse strain (B6Tg2576) led to sig-
nificantly increased levels of atherosclerosis, which
correlated positively with cerebral Aβ deposits [48]. Of
particular interest, when these mice were maintained on a
normal chow diet that did not induce atherosclerosis in
wild type littermates, B6Tg2576 mice developed early
atherosclerotic lesions in the aortic root, suggesting that
Aβ promotes atherogenesis. The convergence of risk fac-
tors for AD and atherosclerosis suggest that these chronic
inflammatory diseases may have overlapping mecha-
nisms of pathogenesis in which cholesterol levels and
lipid peroxidation play a central role.
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